MENU
TCRX
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION
TScan Therapeutics (TCRX) Ownership - Who owns TScan Therapeutics?
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer... Show more
Profile
Industry
N/A
Address
830 Winter Street
Phone
+1 857 399-9500
Employees
154
Web
https://www.tscan.com
Details
Group
Domestic Stock Funds
Category
Biotechnology
Capitalization
94.51M
P/E Ratio
N/A
Total Cash
251.69M
Projected Growth
N/A
Total Debt
97.04M
Revenue
4.42M
Risk (Beta)
1.04
Dividend Yield
N/A
Total Cash/Share
4.45
Total Debt/Equity
N/A
Revenue/Share
0.04 USD as % of share price
Fundamentals
TCRX
Capitalization
94.5M
P/E Ratio
N/A
Risk (Beta)
1.04
Dividend Yield
N/A
Total Cash
252M
Total Cash/Share
4.45
Total Debt
97M
Total Debt/Equity
N/A
Projected Growth (PEG Ratio)
N/A
Revenue/Share (as % of the share price)
0.04%
Revenue
4.42M
ROE
N/A
Book Value
210M
P/B Ratio
0.45
Cash Flow
N/A
Earnings
-1.08
Average Daily Volume YTD
N/A
Common Shares Outstanding - Security Level
6K
Current Ratio
8.55
Current Revenue Per Employee
10801.00
Dividends Per Share - Security
N/A
EBITDA
-124.58M
Float
N/A
Float - Current
N/A
Gross Income Margin
N/A
Revenue To Assets
-45.85
Shares Held By Institutions
59.4M
Shares Outstanding - Current
56.6M
Total Liabilities
123M
Total Volume MTD
N/A
Value
1
Gain YTD
-45.066
View a ticker or compare two or three
VS
VS
Show more...
Interact to see
Advertisement
Advertisement
A.I.Advisor
published price charts
These past five trading days, the stock lost 0.00% with an average daily volume of 0 shares traded.The stock tracked a drawdown of 0% for this period. TCRX showed earnings on August 12, 2025. You can read more about the earnings report here.
A.I. Advisor
published General Information
General Information
Industry Biotechnology
Profile
Fundamentals
Details
Industry
N/A
Address
830 Winter Street
Phone
+1 857 399-9500
Employees
154
Web
https://www.tscan.com